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dard” valuation method. The aim of this study is to review and
critique temporary health state valuation methods and identify
areas for future research. METHODS: We reviewed the literature
and evaluated preference-based temporary health state valuation
methods according to ﬁve criteria: (1) Consistency with quality-
adjusted life year theory; (2) Ease of use; (3) Relevance to tem-
porary health state-speciﬁc domains; (4) Sensitivity to health
state duration; and (5) Extent of bias. Our goal was to provide a
critical assessment of methods that could be used to obtain values
for use in cost-utility analyses. RESULTS: We identiﬁed six tem-
porary health state valuation methods. Methods modiﬁed stan-
dard approaches by prorating utilities, using a chained approach,
or trading-off waiting time or sleep instead of death in a time
trade-off. These modiﬁcations capture the effect of duration
better than standard methods. The strength of methods varied.
No method was well tested for validity and reliability with
respect to temporary health states. CONCLUSION: The litera-
ture on temporary health state valuation methods is sparse and
inadequate. Our critique did not identify a method that is appro-
priate for valuation of all temporary health states. Selection of
the most appropriate method should depend on the duration of
and type of temporary health state being considered. Further
research should focus on the validity, reliability and feasibility of
valuation under different circumstances. Utility values obtained
using temporary health state methods should be compared to
those using standard methods to quantify biases.
PMC31
CONTROLLING MEASUREMENT ERROR OF
PATIENT-REPORTED-OUTCOMES DURINGTHE
IMPLEMENTATION STAGE OF CLINICALTRIALS
Gnanasakthy A
Novartis Pharmaceuticals, East Hanover, NJ, USA
OBJECTIVE: Measurement errors may be introduced in the
development, cultural adaptation, implementation, and analysis
of PRO assessments. Recent publications provide guidance to
minimize measurement errors during the development and cul-
tural adaptation stages. Very little guidance is available to
control errors, especially in multinational studies, introduced
during the implementation of PRO assessments. The objective of
this abstract is to highlight errors that may be introduced during
the implementation stage, speciﬁcally during the production of
data capture modules (e.g. Case Report Forms)for multi-national
studies. METHODS: A rigorous process was put in place to
monitor errors introduced during the CRF development process
with the aim of having a library of PRO instruments readily
available for use in clinical trials. After typesetting, CRF pages
were proof read by three independent reviewers including a
native speaker. Suspected errors including poor grammar and
typographical errors found in original PRO instruments were
reconciled with author’s permission and documented. RESULTS:
A total of 40 PRO instruments were used in 39 Phase III multi-
national studies involving 69 languages in 2006–2007. Three
instruments had multiple versions for the same language and the
author of another instrument did not have a list of available
translations. Two types of errors were found at the ﬁnal stage of
proof reading by native speakers. The ﬁrst, ambiguous or out-
dated terminology. The second, typesetting errors which may
have altered the meaning of the phrase or question. CONCLU-
SION: An adequate process must be in place to monitor, docu-
ment and minimize errors that may be introduced during the
implementation stage of PRO assessments. Failure to do so,
especially in multi-national studies, may invalidate the resources
spent during the development and translation stages and increase
the Company Risk.
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OBJECTIVES: The objective of the study is to derive an algo-
rithm to predict a cohort preference-based SF-6D index using the
eight mean health dimension scores when patient level data is
not available. METHODS: Health related quality of life data
(n = 6890) collected from patients with a wide range of health
conditions was used to explore the relationship between the
SF-6D and the eight dimension scores. Ordinary least square
regressions were derived using the eight dimension scores and
ﬁrst order interactions. Models were assessed for goodness of ﬁt
and predictive abilities using standard statistics such as variance
explained; residuals and the proportion of predicted values
within the minimal important difference. The models were also
compared on their abilities to predict mean cohort SF-6D scores
using mean dimension scores using both within-sample and
out-of sample published datasets. RESULTS: The OLS equations
obtained explained over 83% of the variance in the individual
SF-6D scores. While the models over-predict the lower health
states and under-predict the higher SF-6D scores on the indi-
vidual level, the mean absolute errors are in the region of 0.040.
When using mean dimension scores from within-sample sub-
groups and out-of sample published datasets, the majority of
predicted scores were well within the minimal important differ-
ence (0.041) for the SF-6D. The models are reasonably accurate
at predicting incremental values between study arms (mean error
0.012; mean absolute error 0.017) and when predicting incre-
mental changes over time (mean error 0.004; mean absolute
error 0.024). CONCLUSION: This paper presents a mechanism
to estimate a mean cohort preference-based SF-6D score from
published mean dimension scores. This study is unique in that it
uses published mean statistics to validate the results. The out-of
sample validation demonstrates the algorithms can be used to
inform both clinical and economic research. Further research is
required in different health conditions.
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OBJECTIVES: The objective of the study is to derive a method to
predict a cohort EQ-5D preference-based index score using pub-
lished statistics of the eight dimension scores describing the SF-36
health proﬁle. METHODS: Ordinary least square regressions are
used to obtain models from patient level data covering a wide
range of health conditions. The eight dimension scores, the
squares age and gender are used to derive a relationship with the
EQ-5D index. Models obtained are compared for goodness of ﬁt
using standard techniques such as descriptive statistics, variance
explained, the residuals and the proportion of values within the
minimal important difference. Predictive abilities are also com-
pared when using summary statistics from both within-sample
subgroups and datasets published studies. RESULTS: The models
obtained explain more than 56% of the variance in the EQ-5D
scores. For the individual predicted values, the mean predicted
EQ-5D score is correct to two decimal places and the mean
absolute error is approximately 0.13. Using summary statistics to
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